measles

As US measles cases hit a 35-year high, biotech companies like Invivyd are developing monoclonal antibody treatments for measles, though they are years away from availability.

With measles cases reaching a 35-year high in the US due to declining vaccination rates, biotech companies and researchers are developing monoclonal antibody treatments for the disease, though these therapies may take years to become available.